Evidence map›Paper›PMID 23185384›Full record

ArticlePloS one2012

RIN3 is a negative regulator of mast cell responses to SCF.

Christine Janson, Noriyuki Kasahara, George C Prendergast, John Colicelli

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Genome assemblies forFrontiers in genetics · 2024
    Article
  5. Ras and Rab Interactor 3: From Cellular Mechanisms to Human Diseases.Frontiers in cell and developmental biology · 2022
    Review
  6. Genetic Determinants of Paget's Disease of Bone.Current osteoporosis reports · 2021
    Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Genetics of Paget's disease of bone.Current osteoporosis reports · 2014
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Christine JansonMolecular Biology Institute, Department of Biological Chemistry, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, United States of America.
Noriyuki Kasahara
George C Prendergast
John Colicelli
University of California, Los Angeles · USLankenau Institute for Medical Research · US

Funding

Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Samuel Wheeler French · 1985 to 2026
$134.5M
UCLA NIGMS T32 Program AssessmentT32GM007185 · NIGMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI TORRES, JORGE · 1985 to 2020
$21.7M
Pilot and Feasibility ProgramP30DK041301 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ROZENGURT, JUAN ENRIQUE · 1990 to 2019
$18.0M
RhoB Signaling in Cancer Suppression and Cell SuicideR01CA100123 · NCI · LANKENAU INSTITUTE FOR MEDICAL RESEARCH · PI PRENDERGAST, GEORGE C · 2003 to 2007
$1.7M
A Novel Screen for Compounds that Outflank BCR-ABL Drug-ResistanceR01CA136699 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI COLICELLI, JOHN J. · 2009 to 2011
$937k
NCI NIH HHS CA136699NCI NIH HHS P30 CA016042NCI NIH HHS R01 CA100123NCI NIH HHS R01 CA136699NIDDK NIH HHS P30 DK041301NIGMS NIH HHS GM007185NIGMS NIH HHS T32 GM007185
6 · The paper itself

Abstract

Stimulation of the receptor tyrosine kinase KIT by Stem Cell Factor (SCF) triggers activation of RAS and its downstream effectors. Proper KIT activation is essential for the maturation, survival and proliferation of mast cells. In addition, SCF activation of KIT is critical for recruiting mast cells to sites of infection or injury, where they release a mix of pro-inflammatory substances. RIN3, a RAS effector and RAB5-directed guanine nucleotide exchange factor (GEF), is highly expressed and enriched in human mast cells. SCF treatment of mast cells increased the amount of GTP-bound RAB5, and the degree of RAB5 activation correlated with the expression level of RIN3. At the same time, SCF caused the dissociation of a pre-formed complex of RIN3 with BIN2, a membrane bending protein implicated in endocytosis. Silencing of RIN3 increased the rate of SCF-induced KIT internalization, while persistent RIN3 over-expression led to KIT down regulation. These observations strongly support a role for RIN3 in coordinating the early steps of KIT endocytosis. Importantly, RIN3 also functioned as an inhibitor of mast cell migration toward SCF. Finally, we demonstrate that elevated RIN3 levels sensitize mastocytosis cells to treatment with a KIT tyrosine kinase inhibitor, suggesting the value of a two-pronged inhibitor approach for this difficult to treat malignancy. These findings directly connect KIT activation with a mast cell-specific RAS effector that regulates the cellular response to SCF and provide new insight for the development of more effective mastocytosis treatments.

Indexed as

Gene Expression RegulationBenzamidesCarrier ProteinsCell MovementCell ProliferationEndocytosisGene SilencingGuanine Nucleotide Exchange FactorsHumansImatinib MesylateImmunohistochemistryInflammationLipopolysaccharide ReceptorsMast CellsMastocytosisPiperazinesBenzamidesCarrier ProteinsGuanine Nucleotide Exchange FactorsImatinib MesylateLipopolysaccharide ReceptorsPiperazinesProto-Oncogene Proteins c-kitPyrimidinesrab5 GTP-Binding ProteinsRIN3 protein, humanStem Cell Factor

Identifiers

PMID23185384
PMCPMC3502454
OpenAlexW2051010647

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.